Every Business Has an Origin Story: A Lesson in Branding

“We’ve lost our way.”

I’ve heard this from clients countless times. And it’s no wonder people are saying this: today’s businesses have to evolve very quickly because employees rarely stay in one job for their whole careers and technology is growing so fast that it’s a constant battle to keep up with the next new thing. The stress can be overwhelming. I went through it myself at a time before Sub Rosa was what it is today.

Often the best way we inspire our clients for the future is when we connect them to the most indigenous part of themselves, to understanding why they were founded and why they are still here.

We help them reconnect by exploring their:

Origin story: How it all began.

Language: Your shared lexicon.

Traditions: How you engage your community and acknowledge milestones.

Purpose: Your reason for being.

Think about it: these are the building blocks of every thriving community. Whether in a tribe, a religion, or a corporation, these four building blocks are what provide meaning and create the connective tissue that forms a lasting foundation from which to grow.

A Tradition In Denim

At a meeting with a Levi’s executive, he told us that the company had missed a major opportunity by not participating in the “premium denim boom,” and it was now suffering both reputational and financial challenges. The “premium denim boom” had occurred when a number of high-fashion brands entered the market and began selling $200-plus pairs of jeans. During that time, Levi’s had maintained its traditional price point of around $39, and as a result, its jeans had acquired a low-end reputation and were considered less chic and no longer fashionable. The company was experiencing a significant sales slump.

We had been involved in a similar conversation not too long before with Absolut Vodka, whose management felt the company had missed out on the “premium vodka boom.” Apparently this premium boom was a phenomenon in a number of sectors. In the 1980s, Absolut was a top-shelf vodka. But in the 1990s, competitive vodka brands such as Grey Goose and Ketel One came onto the market with a more premium-priced product.

Absolut, like Levi’s, had stuck to its price point and dropped to a midtier status, losing market share to the new entrants. Ultimately Absolut found a way out of this by creating its own specialty, limited-edition lines, such as Absolut Brooklyn, created in partnership with Spike Lee, and premium-crafted versions such as Absolut Elyx, which was sourced and distilled in a manner designed to compete with other premium vodkas.

Levi’s needed a strategy to help it overcome a similar challenge. They had hired Wieden + Kennedy, a wellknown and successful advertising agency, to help rejuvenate the brand. Their campaign, which would later be known as “Go forth,” was being shot by a famous fashion photographer, and it would draw on inspirational imagery and language from well-known American authors such as Walt Whitman and Jack Kerouac. It would depict a new era of American nostalgia, and it was sure to capture attention. Levi’s wanted our help in turning that attention into action.

Our job was to make sure that once they had people’s attention, there would be have something to act upon and a real reason to care about the brand. This is the sort of integrated, complex challenge we love to solve, and we first began by focusing on the brand as we knew it. The company made denim and sold jeans (primarily) at a modest price point. They had once been the jeans of Marlon Brando and Steve McQueen and later the jeans of rock stars from the Rolling Stones to the Ramones. But somehow the company had lost its grip. We asked what had come before Brando and Jagger? Levi’s had begun making jeans in 1853. What had the company stood for then, and what was its origin story?

It’s fairly common knowledge that Levi Strauss & Company started out as a brand of pioneers. The men who had set out for the gold hiding in the uncharted lands of California during the famous Gold Rush of 1849 were known as the 49ers, and they had taken a big gamble, often risking life or death, to try to strike it rich. Those tough men needed tough jeans, and that’s what Levi Strauss produced. They had reinforced stitches and held up during hard work.

Over the coming decades, Levi’s rugged jeans continued to be a staple of the hardscrabble masses. Factory workers, laborers, farmers, and all manner of builders and fixers wore Levi’s as they headed out to work. They were the jeans that helped build America. We had to tell the story in a way that would ignite a newfound interest in the hearts and minds of new consumers and (hopefully) would bring back some customers the brand had lost along the way.

Panning for Gold

We asked ourselves, “Who are our modern-day pioneers?” After all, we’re not settling the West anymore, and many hard-labor jobs have since been shipped overseas. We wanted to find people who were embodying that spirit of progress and hard work and pull them into a new conversation, one that celebrated their sense of craft, of making things, of the integrity that comes from doing that kind of work well.

After a few weeks of development, we had created a program we called Levi’s Workshops and sent it off to Erik and his team. We admitted that what we were giving them was “only 75 percent of the plan.” The rest would have to be left open to serendipity. We knew we were going into the unknown, like the gold panners of the nineteenth century, and similarly we knew something about what we’d find but not everything. Like any good prospector, we knew to leave room for the unexpected. After all, you never know where you might strike it rich.

Together, our two teams became one unit. It didn’t take long for us to develop a working and speaking lingo, a kind of shorthand. When we said “pioneer,” we weren’t thinking of a grizzled old prospector chewing tobacco and swilling whiskey, we were imagining today’s artists, craftspeople, designers, teachers, and builders. When we said, “Go forth,” we knew we were looking for the spirit of adventure and discovery we wanted people to feel when they interacted with the brand. This shared language was built upon the origins of the brand, yet it was contemporized and translated for today. It drew our own teams closer together and became contagious throughout Levi’s organization.

Within months we were ready to open our first Levi’s Workshop in the heart of San Francisco’s Mission District, which was chosen because the neighborhood was thriving with diversity and craft. It felt like a pioneer town for new ideas.

The programming was built on collaborations with “pioneers” from the Bay Area. Right down the street from us, the writer Dave Eggers had opened his first whimsical tutoring location (themed as a pirate shop), where volunteers taught kids the value of creative writing. We partnered with them and paired the kids’ writing with artists who created original artwork for their stories. The kids got to watch the books being printed in the shop, and they were dazzled as they flipped through a book that had come to life from their story.

We brought in Alice Waters, a pioneer of California cuisine, and designed a beautiful letterpress harvest calendar that supported the work of her charity, the Edible Schoolyard Project. She hosted a small dinner in the space and signed copies for us to sell at auction, with the proceeds benefiting her cause as well as the Levi Strauss Foundation, the company’s charitable organization.

Not only did each project bring into the workshop a compelling pioneer to help create programming, but every piece of programming was designed to reach different subcultures and niche audiences in the Bay Area with authenticity.

These new traditions we were creating for the brand were building on Levi’s legacy of engaging with powerful subcultures. From gold-panning pioneers to punks on the Bowery, Levi’s has always been the uniform of the brave and status quo challenging. We built programming for the literary community, musicians, foodies, inner-city youths, and more. If you were willing to “Go forth” and try something different, we wanted you to know that Levi’s was with you.

Our work with Levi’s showed us the value of looking back to a brand’s indigenous roots and bringing thoughtful inspiration and wisdom into the present. Admittedly not every company has a brand that is more than a hundred years old, but every business does have an origin story.

Excerpted from Applied Empathy by Michael Ventura. Copyright © 2018 by Seed Communications, LLC d/b/a Sub Rosa. Excerpted with permission by Touchstone, an imprint of Simon & Schuster, Inc.

You can purchase Applied Empathy on Amazon.

On the President’s Drug Cost Plan, Three Important Concerns

Part 1. Restricting access under Medicare Part D 

The Trump administration is out with its plan to lower the cost of prescription drug for America’s patients. The plan rightly rejects the flawed schemes we hear regularly from pundits and the media – importation and direct government price negotiation in Medicare – that together would weaken the safety of our nation’s pharmaceutical supply chain, reduce patient access and do little to lower costs.

The plan contains some positive ideas, such as encouraging value-based pricing agreements, fixing the flaws in the 340B drug discount program, limiting pharmacy gag clauses, and passing rebates through to patients in Medicare Part D and capping their out-of-pocket costs. However, buried in the details are proposals that could harm the ability of patients to get the medicines they need both now and in the future.

Today, BIO is starting a blog series that will highlight three proposals in particular that could pose significant challenges to patients. As the first in a three-part series, this blog will look at proposals in the president’s drug pricing plan that would affect a popular prescription drug program for America’s seniors.

Restricting access under Medicare Part D. 

The Medicare Part D prescription drug program has been a remarkable success for both seniors and taxpayers.

  • The program cost $349 billion less over 10 years than initially expected;
  • Average premiums dropped 3% in 2018 to less than $34 per month; and
  • Hospital admissions for seniors have also dropped by 8%.

It’s no wonder then that nearly 90% of seniors are satisfied with the program.

Medicare Part D generally covers medicines that patients buy at a retail pharmacy and take themselves. The private health plans administering the Part D program are required to provide at least two drugs for each class of drugs that exists. Then there are six “protected classes” of drugs for patients facing particularly devastating diseases like cancer, HIV and mental illnesses. Health plans are required to cover “all or substantially all” medicines that fall within these protected classes.

Current policies help provide seniors and people with disabilities with choices, and more choices means more competition that can lead to lower costs. However, under the Trump administration’s proposal, health plans would only be required to provide one drug per class, down from the current requirement of at least two. The administration may also eliminate some of the protected classes altogether. These changes would leave doctors and patients with fewer options, forcing beneficiaries to pay more if the medicines their doctors prescribe aren’t covered.

Health plans would also be allowed to increase the use of so-called utilization tools – such as “step therapy” or “prior authorization.” These bureaucratic hurdles are already far too common, and while these “tools” may help insurers protect their bottom line, they also bury doctors in paper work and make it harder for patients to get the right medicines at the right time. 

The nation’s biopharmaceutical innovators support taking steps to strengthen the Medicare Part D program. That effort should focus on lowering seniors’ out-of-pocket costs and ensuring they have broad access to the medicines they need.

Stay tuned for the second part of this three-part blog series, which will look at proposed changes to the Medicare Part B program.

BIO 2018 Wednesday Keynote: I’ll have what she’s having

The famous line-”I’ll have what she’s having”-from the movie classic When Harry Met Sally is on every list of best movie quotes and is displayed above the table where the scene was shot in Katz’s Delicatessen in NYC. The famed director of this and countless other hit movies is the keynote speaker for Wednesday morning, June 6 during the BIO International Convention. Rob Reiner made history with his role as Michael Stivic, or Meathead as his character’s father-in-law called him, in “All in the Family”-a sitcom that broke ground tackling issues like race, rape and homosexuality.  His career grew to include directing, producing and even political activism.

In 2015 Reiner directed his most personal film, Being Charlie, which was written by his son Nick who suffers from drug addiction. The fictional piece follows the struggles of a troubled teenager who runs away from a rehab facility and must face the consequences.

BIO’s President and CEO, Jim Greenwood, who will interview Reiner at the Wednesday, June 6 keynote from 9 – 10:30 AM ET, had this to say about the acclaimed director: “Rob is a passionate advocate for those living with substance abuse disorders and addiction. His poignant story of helping his son overcome his battle with drug addiction will inspire attendees and our industry in its quest to discover next generation, non-addictive pain therapies. I look forward to our discussion.”

Registration is open for this year’s event, which promises to be the most comprehensive biotech convention in the world. In addition to the 19 educational tracks covering all sectors of biotechnology, including genome editing, opioids, digital health and more, BIO 2018 will feature the most influential global leaders in this year’s lineup of Super Sessions. Recent speakers announced include:

  • Johnson & Johnson Innovation – Marianne De Backer
  • Genentech – Dr. Thomas Zioncheck
  • Takeda – Rejeev Venkayya
  • Biogen – John Pieracci
  • Pfizer – Bob Smith
  • FUJIFILM Diosynth Biotechnologies – Steve Bagshaw
  • Bristol-Myers Squibb – Dr. Thomas J. Lynch, Jr.
  • Sanofi Genzyme – Bill Sibold
  • Harvard Medical School – Scott D. Solomon
  • Flatiron Health – Marta Bralic
  • Verily – Dr. Luba Greenwood
  • Tufts University School of Medicine – Kenneth Kaitlin
  • NOVOVAX – Stanley Erck
  • Seqirus – Gordon Naylor

Other notable programing includes:

  • BIO One-on-One Partnering™ – Expected to top last year’s more than 41,000 individual meetings held over the course of four days.
  • Engaging exhibits such as the Patient Advocacy Pavilion, Emerging Innovators Zone, Digital Health Zone, and Start-Up Stadium – a “Shark Tank”-like program where startups present to leading subject-matter experts in the industry.

This year the Convention will be making an official Guinness World Records® attempt for the “Largest Business Partnering Event.” The industry-leading BIO One-on-one Partnering™ will facilitate nearly 1,300 partnering meetings per hour during the event with the grand total expected to approach over 44,000 business-to-business meetings over the course of four days.

Looking forward to more updates on the Convention? Keep following the posts here on the blog and sign up for news updates.

Keene State Convenes Statewide Biotechnology Leaders to Help Build Workforce

Keene State has an important role in New Hampshire’s biotechnology workforce by preparing graduates in the field. During this event, business …

Do It: Replace a Toilet – Today’s Homeowner

Do It: Replace a Toilet

Whether a toilet is being replaced or just temporarily removed to allow flooring repairs or replacement, the process is pretty much the same.

2017 Rosalind Franklin Award Recipient: CRISPR has the potential to address important challenges

As we’ve covered here before, gene editing holds tremendous promise in advancing modern agriculture. And it’s not hard to see why. With gene editing tools like CRISPR, researchers have the capability to engineer plants to be, amongst other things, better for the environment, more nutritious and disease-resistant.

BIO’s 2017 Rosalind Franklin Award for Leadership in Biotechnology recipient Vonnie Estes is an agtech innovation consultant who is tuned into the current conversations happening at farms and agricultural businesses across America. And a lot of those conversations revolve around the new gene editing technology.

In a blog for Ag Funder News, Estes entertains the question: Should You Be Using CRISPR for Your Ag Business? In addressing this question, Estes starts by outlining the “number of challenges” that must be addressed before CRISPR becomes widely adopted, including the regulatory landscape:

One of the biggest restrictions to the global commercial use of gene editing is uncertainty around regulation. The USDA just ruled it would not regulate plants that could otherwise have been developed through traditional breeding techniques, as long as they are not developed using plant pests. This is a good start, however, there are a limited number of improvements that can be made within these criteria. If Agrobacterium is used as a delivery method or a greater number of genes are edited – which will be needed for complex traits – it will be considered GMO and more highly regulated. Most crop genetics and food production companies operate globally: shipping seeds, plant materials, or final foods worldwide. The EU has not yet ruled if gene edited crops fall under the genetically modified organism rule, although there is some indication that may change. Until this is clear, many crop genetics companies will not risk the potential trade barriers of using gene editing technology.

Vonnie Estes, Agtech Innovation Consultant

Estes then goes on to note that because of the contentious debate around GMOs and the public’s confusion around the difference in the science behind the two technologies, gene editing will be susceptible to similar pushback. However, Estes believes the younger generation of consumers will be receptive, especially if the benefits are clearly defined and explained:

Consumers are more likely to accept the technology if they get a direct benefit, such as better taste or higher nutritional value. Food producers are right to be cautious, but I’m hoping the younger, tech-savvy, more demanding food consumers will be accepting of gene editing technology.

Nevertheless, the potential for the technology to solve some of the world’s food challenges is encouraging and the science community is enthusiastic:

As the world’s population rapidly approaches eight billion, modern food production methods will need a radical transformation. Gene editing can certainly help meet that challenge of production, along with making food more flavorful and nutritious. The path to widespread usage is currently complicated – from the science to consumer acceptance. But with the tremendous enthusiasm of the research community, gene editing technologies will improve rapidly along with the all of the techniques and technologies needed to support crop use.

Read Vonnie Estes full piece at AgFunderNews.com.

2018 World Congress: Start Planning with BIO’s Partnering Webinar

It’s hard to believe but the 2018 World Congress on Industrial Biotechnology in Philadelphia is only two months away! With the tri-state region of Delaware, New Jersey and Pennsylvania ranking as one of the top markets for biotechnology and home to many startups, this year’s World Congress is perfect for those looking to establish lasting partnerships in the industrial biotechnology industry.

The BIO One-on-One Partnering™ system takes the stress out of coordinating and scheduling meetings at the World Congress, so you can focus on your partnering strategy. Through BIO’s One-on-One Partnering, attendees can request meetings, message potential partners pre- and post-World Congress and create company profiles to showcase your company’s mission or latest breakthrough.

In case you missed it, BIO has put together a One-on-One Partnering Webinar to get you up to speed on how the system works. In the webinar, BIO’s Director of Partnering Products & Services Willie Reaves, along with BIO’s Director of Industrial and Environmental Policy Stephanie Batchelor, present a comprehensive overview of everything that can be accomplished in the platform.

From accessing attendee lists to reviewing programming and plenary details to strategies for getting the most out of your meetings, the Partnering Webinar covers everything you need to know to master BIO’s One-on-One Partnering system. Here’s a sneak preview of what is covered in the webinar:

  • What’s new at the 2018 BIO World Congress on Industrial Biotechnology
  • Comprehensive overview of World Congress programming, including plenaries, education tracks and more
  • Tips and Tricks for getting the most out of your partnering meetings
  • Tutorial of the BIO One-on-One Partnering system
  • Q&A with Webinar Presenters

In 2017, the BIO World Congress hosted 2,130 partnering meetings in just 3 days – a 9% increase from the number of meetings held in 2016. And with a 123% increase in partnering meetings since the 2014 World Congress, we expect 2018 to be even bigger. Don’t miss out on making lasting partnerships at the 2018 World Congress and be sure to view the Partnering Webinar.

If you haven’t done so yet, register to attend the 2018 World Congress.

And for those that have already registered to attend the World Congress in July and received their login information, BIO’s One-on-One Partnering is now open. Start building out your company’s profile and use BIO’s tips and tricks to get a head start, so you can begin partnering day one in Philadelphia!

Nanoparticles Market In Biotechnology And Pharmaceutical Sectors Market Vendor Overview By …

Nanoparticles Market In Biotechnology And Pharmaceutical Sectors Market report is prepared based on the in depth analysis with inputs from industry …

Food Evolution Writer/Producer Trace Sheehan to Keynote Food & Ag Program at #BIO2018

Trace Sheehan, writer and producer of the highly-acclaimed documentary film Food Evolution, will be a keynote speaker at BIO’s International Convention in Boston, the Biotechnology Innovation Organization (BIO) announced today.

Since its premier in November 2016, Food Evolution has contributed to a robust discussion about science, facts, and food. The film focuses on the GMO debate because the filmmakers found it to be emblematic of the public misunderstanding about the science of food and food sustainability. In his keynote on Tuesday, June 5, Sheehan will share his experience in making the film and explain how the process influenced his own opinions along the way.

Other food and ag-related programming to note:

On Monday, June 4, BIO will host “One Health Day,” a half-day of speakers and panel discussions focusing on how the One Health concept – the interconnectivity of human, animal and environmental health – can help address today’s greatest challenges. The program starts with a keynote presentation and panel introducing the One Health concept before diving right into an exploration of the business case for One Health with a panel of senior leaders from the private sector. The program also looks to global perspectives on One Health policy development and insights into U.S. government funding and research decisions.

On Tuesday, June 5, a second half-day of programming is dedicated to food and agricultural innovation in our “Food, Health, and Environmental Future Day.” This program, featuring Keynoter Trace Sheehan, will include this series of panel discussions:

  • A Two-Part Food Innovation Dialogue: Cutting-Edge Food, Health, & Environmental Products and Tools…Coming to a Grocery Store Near You(?)

    Part 1 looks at the landscape of innovation now and on the horizon, including applications of genome editing in animals and plants, microbes for soil health, and more…

    Part 2 brings the food value chain together in a conversation about consumer preferences and trends around sustainability and transparency, and how the innovations discussed in Part 1 will fit in today’s (and tomorrow’s) marketplace.

  • Biotech in Our Backyard: New England’s Booming Food and AgTech Innovation Ecosystem
  • AgTech Investment: Opportunities for Plants, Animals, Microbes, and Beyond…

On Wednesday, June 6 and Thursday, June 7, BIO’s 2018 International Convention also features a track dedicated to Genome Editing, including programming about Engaging Our Nation and Our World in the Era of Gene Editing and genome editing as The Next Frontier in Agriculture.

Held in conjunction with BIO, CRISPRCon: Conversations on Science, Society and the Future of Gene Editing will take place on June 4-5 at the Boston Seaport Hotel & World Trade center (Separate registration is required).

The BIO International Convention, the world’s premier life sciences event, will take place at the Boston Convention & Exhibition Center, June 4-7.  Hosted by BIO, the 2018 event is expected to attract more than 16,000 attendees and 1,800 exhibitors from 74 countries.

Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials.

Negative Market Storylines Are Gaining Traction

Click to view a price quote on QQQ.

1 19 20 21 22 23 46